Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Liquid biopsy for non-invasive molecular characterization and measurable residual disease analysis in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

BFBenedikt FärberEDEva DazertLRLuna Reifenrath

Discussion

Loading...

Member takes

Overview

Proof-of-concept study shows liquid biopsy detects molecular markers in multiple myeloma, suggesting new monitoring methods.

Key Points

  • Molecular characterization through ctDNA and next generation sequencing improves diagnosis and monitoring in multiple myeloma.
  • Liquid biopsy revealed specific biomarkers in 7 out of 10 evaluated multiple myeloma patients, indicating its diagnostic potential.
  • Assessment using next generation sequencing and metabolomics explored disease states and treatment responses in multiple myeloma patients.
  • ctDNA analysis enhances monitoring of disease progression and supports predictive modeling, calling for its integration in clinical practice.

Cite This Study

Färber et al. (2025) studied this question.

synapsesocial.com/papers/69362f4b4fa91c937236d7d1https://doi.org/10.1182/blood-2025-2208
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pilot study of cell-free DNA (cfDNA) for measurable residual disease monitoring following autologous hematopoietic cell transplant in multiple myeloma2025 · 2 citations
  2. 2Minimally invasive characterization of peripheral blood measurable residual disease in multiple myeloma using high‐sensitivity detection of ctDNA by next‐generation sequencing2026 · 1 citations
  3. 3Integrated cell-free DNA and RNA sequencing recapitulates bone marrow genomic and transcriptomic alterations in multiple myeloma2025 · 1 citations
  4. 4Whole genome sequencing of cell-free DNA for assessment of minimal residual disease in high-risk smoldering multiple myeloma2025
  5. 5Circulating Tumor DNA in Multiple Myeloma: Current Insights and Future Perspectives2026